English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.
Tag: New England Journal Of Medicine
Optical Coherence Tomography May Improve Safety and Outcomes for Stenting Procedures in Heart Disease Patients Compared to Conventional Angiography
Results from a large-scale clinical trial results could increase usage of high resolution imaging for guiding interventional coronary procedures
University Hospitals Research Published in New England Journal of Medicine Shows Minimally Invasive Procedure Saves Most Patients with Severe Vascular Disease from Amputation
A study, co-led by University Hospitals Harrington Heart & Vascular Institute, could lead to the first FDA approval of a therapy giving thousands of patients hope for an alternative to amputation.
Selwyn Rogers named associate editor of prestigious New England Journal of Medicine
Founding director of UChicago Medicine’s Level 1 trauma center is first surgeon to hold the journal position in more than a decade.
Heart Rhythm Disorders: What You Need to Know
Heart rhythm disorders like atrial fibrillation and sudden cardiac arrest have made headlines in recent months, prompting many to learn more about how the heart beats.
Medicamento brentuximab vedotina pode melhorar a sobrevida geral de pacientes com linfoma de Hodgkin
Um estudo conduzido por pesquisadores do Centro de Câncer da Mayo Clinic descobriu que adicionar o brentuximab vedotina ao tratamento quimioterápico padrão aumenta a taxa geral de sobrevida de pacientes com linfoma de Hodgkin, em comparação com o padrão de tratamento atual que usa somente a quimioterapia.
New research uncovers how cancers with common gene mutation develop resistance to targeted drugs
A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. Their work shows that, far from adopting a common route to becoming resistant, the cells take a strikingly diverse set of avenues, often several at a time. The findings, reported online today in the New England Journal of Medicine, underscore the need for new drugs that inhibit KRAS differently than current agents do.
CAR T-cell therapy generates lasting remissions in patients with multiple myeloma
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
Study findings improve accuracy of breast cancer risk estimates for women with no family history
A new multi-institution study led by Fergus Couch, Ph.D., a Mayo Clinic pathologist, provides more accurate estimates of breast cancer risk for U.S. women who harbor inherited mutations in breast cancer predisposition genes.
Existing Class of Drugs May Improve Neurological Function in Patients with Rare, Aggressive Genetic Disorder
New findings show that some patients with a rare and aggressive form of leukodystrophy may benefit from receiving treatment with a class of targeted therapy drugs that could improve their neurological function.
CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.